TEL AVIV, Israel, Nov. 2, 2017 /PRNewswire/ -- Therapix Biosciences
Ltd. (NASDAQ: TRPX), a specialty clinical stage pharmaceutical
Company specializing in the development of cannabinoid-based drugs,
announced today that it will host a conference call and webcast on
Thursday, November 9, 2017, to
discuss results for the period ended September 30, 2017 and to provide an update on
current developments with respect to its clinical programs:
Conference Call & Webcast:
Thursday, November 09, 2017, 8:30 am Eastern Time / 5:30 am Pacific Time
Participant Dial-In Numbers:
Toll-Free: +1-877-870-4263
Toll/International:
+1-412-317-0790
Webcast:
https://www.webcaster4.com/Webcast/Page/1726/23160
Replay, available until Nov 16,
2017
Replay Dial-In Numbers:
Toll-Free:
+1-877-344-7529
Toll/International:
+1-412-317-0088
Passcode:
10113655
About Therapix Biosciences:
Therapix Biosciences Ltd. is a specialty clinical-stage
pharmaceutical company led by an experienced team of senior
executives and scientists. Our focus is creating and enhancing a
portfolio of technologies and assets based on cannabinoid
pharmaceuticals. With this focus, the company is currently engaged
in two internal drug development programs based on repurposing an
FDA approved synthetic cannabinoid (dronabinol): THX-110
targets the treatment of the symptoms of Tourette Syndrome; and
THX-130 targets the high-value and under-served market of mild
cognitive impairments and Traumatic Brain Injury (TBI). Please
visit our website for more information at www.therapixbio.com.
Forward-Looking Statements:
This press release contains forward-looking statements
about the Company's expectations, beliefs, and intentions.
Forward-looking statements can be identified by the use of
forward-looking words such as "believe", "expect", "intend",
"plan", "may", "should", "could", "might", "seek", "target",
"will", "project", "forecast", "continue" or "anticipate" or their
negatives or variations of these words or other comparable words or
by the fact that these statements do not relate strictly to
historical matters. Such forward-looking statements used in this
press release include, among other things, references to the
clinical and commercial potential of THX-OSA01 for the treatment of
Obstructive Sleep Apnea. Actual results could differ from those
projected in any forward-looking statements due to numerous
factors. Such factors include, among others, our ability to raise
the additional funding needed to continue to pursue our business
and product development plans, the inherent uncertainties
associated with developing new products or technologies, our
ability to obtain regulatory approval for our product candidates,
our ability to commercialize our product candidates, competition in
the industry in which we operate and overall market conditions. Any
forward-looking statement in this press release speaks only as of
the date of this press release. The Company undertakes no
obligation to publicly update or review any forward-looking
statement, whether as a result of new information, future
developments or otherwise, except as may be required by any
applicable securities laws. More detailed information about the
risks and uncertainties affecting the Company is contained under
the heading "Risk Factors" in Therapix Biosciences Ltd.'s annual
report on Form 20-F dated May 1, 2017
filed with the SEC, which is available on the SEC's website,
www.sec.gov.
For further information:
Investor Contact:
Josh
Blacher, CFO, Therapix Biosciences, josh@therapixbio.com
Therapix Biosciences Ltd.
For further information: +972-3-616-7055
Media Contact:
Susan
Forman, DGI
+1-212-825-3210
View original
content:http://www.prnewswire.com/news-releases/therapix-biosciences-third-quarter-2017-conference-call-and-webcast-scheduled-for-thursday-november-9-2017-300548542.html
SOURCE Therapix Biosciences Ltd